Skip to main content
. Author manuscript; available in PMC: 2022 Aug 10.
Published in final edited form as: Circ Heart Fail. 2021 Aug 10;14(8):e008170. doi: 10.1161/CIRCHEARTFAILURE.120.008170

Figure 6. Elevation of cardiac NAD+ levels alleviates diabetic cardiomyopathy in cKO and control mice.

Figure 6.

(A) Experimental plan. STZ was administered to male cKO and cKO:NAMPT mice to induce diabetes. Cardiac function of cKO and cKO:NAMPT mice was measured at 2, 4, and 8 weeks after induction of diabetes. (B) Cardiac NAD+/NADH ratio were measured. N=4-5. (C) FS and (D) E’/A’ ratio were assessed longitudinally. N=6. Dotted lines indicate average baseline (BL) values of non-diabetic control mice. Numerical values are available in Supplementary Table I. Levels of (E) SOD2-K68Ac, (F) TnI-S150Pi, and (G) TnI-S23/24Pi of indicated hearts were measured by Western blots. N=5. (H) FS and (I) E’/A’ ratio were measured longitudinally in control mice with or without NAMPT expression in the hearts after diabetes induction. N=5. *: P<0.05 to diabetic cKO mice or diabetic-NAMPT mice.